Replimune Group (REPL) News Today
No Replimune Group (REPL) headline in the last 7 days came with a measured price move.
Why Replimune Group (REPL) moved: the full explanation
Every REPL headline we timestamp, with the price move measured one minute after we published it and at the end of the measured window.
What moved REPL — last 7 days
No REPL headline has appeared in our news feed with a measured price move in the last 7 days. This page fills automatically the next time one does.
Our analysis
The FDA Just Approved the First Cancer Virus Therapy Paired With a Checkpoint Inhibitor — and Replimune Made It
Sunday, Aug 9, 2026 · The FDA granted accelerated approval to Replimune's oncolytic virus therapy, TUDRIQEV, in combination with the checkpoint inhibitor nivolumab, for adults with advanced melanoma that progressed on …
Why Was Replimune (REPL) Stock Moving on Aug 9, 2026?
Sunday, Aug 9, 2026 · Replimune is a clinical-stage biotech developing oncolytic virus therapies for cancer. This page tracks what's actually moving the stock — FDA decisions, analyst calls, and trial …